Evaluation of serum Cystatin C as a predictor of eGFR in type 2 diabetic patients with nephropathy
Background: Diabetic nephropathy (DN) is the leading cause of chronic kidney disease (CKD) worldwide. Objective: To evaluate serum Cystatin C as a predictor of eGFR in type 2 diabetic patients with nephropathy. Methods: A cross-sectional analytical study was conducted at the Department of Nephr...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shalamar Medical & Dental College, Lahore, Pakistan
2025-06-01
|
| Series: | Journal of Shalamar Medical & Dental College |
| Subjects: | |
| Online Access: | https://journal.smdc.edu.pk/index.php/journal/article/view/294 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Diabetic nephropathy (DN) is the leading cause of chronic kidney disease (CKD) worldwide.
Objective: To evaluate serum Cystatin C as a predictor of eGFR in type 2 diabetic patients with nephropathy.
Methods: A cross-sectional analytical study was conducted at the Department of Nephrology, Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan, from 10th March to 9th September 2023. Patients with type 2 diabetes (T2D) for more than five years, both males and females, 30 to 65 years of age, and with nephropathy for the last 2 years were included in the study. Serum creatinine, serum Cystatin C (Cys-C), fasting blood sugar (FBS), glycated hemoglobin A1c (HbA1c), total protein, and albumin were measured. A spot urine sample was collected to analyze total urinary protein, albumin, and creatinine levels. The estimated glomerular filtration rate (eGFR) was calculated using the CKD Epidemiology Collaboration (CKD-EPI) equation. One-way ANOVA, Pearson correlation test, and Linear regression analysis were done to analyze the data.
Results: A total of 113 patients were analyzed, with a mean age of 55.5±6.1 years. The mean duration of T2D was 12.0±5.3 years. The mean HbA1c level was 9.1±1.3%. Based on Cys-C levels, the mean eGFR was 71.33±24.8 mL/min/1.73m². Among the participants, 43(38.1%), were suffering from Stage II, 32(28.3%) from Stage I, 32(28.3%) from Stage III, and 6(5.3%) from Stage IV CKD. A majority of 50(44.2%) of study participants had microalbuminuria. A statistically significant (p<0.001) negative correlation between eGFR and Cys-C level was observed among the study participants. Serum Cystatin C is a significant (<0.05) predictor of eGFR.
Conclusion: Serum Cystatin C was a significant predictor of eGFR in type 2 diabetic patients with nephropathy. The strong negative relationship between Cystatin C and eGFR supports its potential role as a valuable marker for assessing renal function in diabetic patients.
|
|---|---|
| ISSN: | 2789-3669 2789-3677 |